Patents by Inventor Michael A. Gelman
Michael A. Gelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957486Abstract: In accordance with some embodiments, systems, apparatus, interfaces, methods, and articles of manufacture are provided for ascertaining aspects of a user, such as the users identity, competence, health, and state of mind. In various embodiments, data is captured about a user via a headset worn by the user. Based on the data, a determination may be made about an aspect of the user, and the user may accordingly be granted or denied access to a resource.Type: GrantFiled: May 1, 2023Date of Patent: April 16, 2024Assignee: SCIENCE HOUSE LLCInventors: James Jorasch, Christopher Capobianco, Isaac W. Hock, Michael Werner, Geoffrey Gelman, Gennaro Rendino
-
Publication number: 20240073322Abstract: In accordance with some embodiments, systems, apparatus, interfaces, methods, and articles of manufacture are provided for providing information incorporating additional data feeds, creating common arrangements, and improving performance in a virtual meeting. In some embodiments, a video conferencing system hosts a customized video conferencing and includes video conference settings data, participant display device data, supplemental data feed data, and processing instructions. The video conferencing system may identify (based on the video conference settings data) a number of data feeds for display on a display screen of each participant in a video conference and (based on the participant display device data) a screen specification for each display screen of each participant. The system may then compute an arrangement for the number of data feeds that fits within an available display area.Type: ApplicationFiled: November 6, 2023Publication date: February 29, 2024Inventors: James Jorasch, Michael Werner, Geoffrey Gelman, Isaac W. Hock, Gennaro Rendino, Christopher Capobianco
-
Patent number: 11884657Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-heteroaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribavirin, and the like.Type: GrantFiled: July 9, 2021Date of Patent: January 30, 2024Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Publication number: 20220017507Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-heteroaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: ApplicationFiled: July 9, 2021Publication date: January 20, 2022Inventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Patent number: 11091472Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: GrantFiled: February 24, 2017Date of Patent: August 17, 2021Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Patent number: 10428060Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: GrantFiled: February 9, 2018Date of Patent: October 1, 2019Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong
-
Publication number: 20190062323Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: ApplicationFiled: February 24, 2017Publication date: February 28, 2019Inventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Publication number: 20180170924Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: ApplicationFiled: February 9, 2018Publication date: June 21, 2018Inventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Patent number: 9926309Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: GrantFiled: February 26, 2016Date of Patent: March 27, 2018Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Publication number: 20160194314Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole or a 5-hetereoaryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: ApplicationFiled: February 26, 2016Publication date: July 7, 2016Inventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong, Mark Smith
-
Patent number: 9370534Abstract: Pharmaceutical compositions containing biocidal co-polymers of poly(styrenes), poly(acrylates), poly(acrylamides), and poly(C1-C6)alkylene glycols are disclosed, along with methods of using the compositions to treat microbial infections in mammals.Type: GrantFiled: April 15, 2015Date of Patent: June 21, 2016Assignee: Wisconsin Alumni Research FoundationInventors: Samuel H. Gellman, Michael A. Gelman, Bernard Weisblum, David M. Lynn
-
Patent number: 9309236Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: GrantFiled: October 5, 2012Date of Patent: April 12, 2016Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong
-
Publication number: 20150224135Abstract: Pharmaceutical compositions containing biocidal co-polymers of poly(styrenes), poly(acrylates), poly(acrylamides), and poly(C1-C6)alkylene glycols are disclosed, along with methods of using the compositions to treat microbial infections in mammals.Type: ApplicationFiled: April 15, 2015Publication date: August 13, 2015Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Samuel H. Gellman, Michael A. Gelman, Bernard Weisblum, David M. Lynn
-
Patent number: 9034309Abstract: Pharmaceutical compositions containing biocidal co-polymers of poly(styrenes), poly(acrylates), poly(acrylamides), and poly(C1-C6)alkylene glycols are disclosed, along with methods of using the compositions to treat microbial infections in mammals.Type: GrantFiled: September 3, 2004Date of Patent: May 19, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Samuel H. Gellman, Michael A. Gelman, Bernard Weisblum, David M. Lynn
-
Publication number: 20150051193Abstract: Compounds and methods are provided for the treatment of pathogen infections. In some embodiments, the anti-infective compounds have broad spectrum activity against a variety of infective diseases, where the diseases are caused by pathogens containing a basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4,5-bisphosphate (PIP-2) to mediate pathogen replication. Also provided are methods of inhibiting a PI4-kinase and methods of inhibiting viral infection. In some embodiments, the compound is a PI4-kinase inhibiting compound that is a 5-aryl-thiazole. The subject compounds may be formulated or provided to a subject in combination with a second anti-infective agent, e.g. interferon, ribivarin, and the like.Type: ApplicationFiled: October 5, 2012Publication date: February 19, 2015Inventors: Jeffrey S. Glenn, Michael A. Gelman, Brandon Tavshanjian, Kevan Shokat, Ingrid Choong
-
Publication number: 20100118200Abstract: According to some embodiments, a digital signage system plays content. According to some embodiments, content may vary based on various circumstances.Type: ApplicationFiled: November 10, 2009Publication date: May 13, 2010Inventors: Geoffrey Michael Gelman, Alexander Epshtegn
-
Patent number: 6914048Abstract: Disclosed are ?-peptides and ?-peptide conjugates that are capable of diffusing or otherwise being transported across the cell membranes of living cells. The ?-peptides contain at least six ?-amino acid residues, at leastsix of which are preferably ?3-homoarginine residues. It has been found that when pharmacologically-active agents are conjugated to these types of ?-peptides, the resulting conjugates (also disclosed herein) are also capable of diffusing or otherwise being transported across the cell membranes of living cells, including mammalian cells.Type: GrantFiled: September 18, 2002Date of Patent: July 5, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Samuel H. Gellman, Naoki Umezawa, Michael A. Gelman, Ronald T. Raines, Terra Potocky
-
Publication number: 20050079150Abstract: Pharmaceutical compositions containing biocidal co-polymers of poly(styrenes), poly(acrylates), poly(acrylamides), and poly(C1-C6)alkylene glycols are disclosed, along with methods of using the compositions to treat microbial infections in mammals.Type: ApplicationFiled: September 3, 2004Publication date: April 14, 2005Inventors: Samuel Gellman, Michael Gelman, Bernard Weisblum, David Lynn
-
Publication number: 20040145114Abstract: Various embodiments of the present invention include a chess clock with a first display facing in one direction and a second display facing in an opposite direction. Each of the first and second displays may display information about a single player of a chess game. Such information may include a time remaining in the game. A chess clock of the present invention may afford spectators and chess tournament directors a view of a player's time remaining from a wide range of vantage points. Various embodiments of the present invention include a chess clock with four displays, two displays corresponding to each of two players. The two displays corresponding to a given player may face in opposite directions. Various embodiments of the present invention include a chess clock suitable for simultaneous use in two separate chess games, or for use in a game of bughouse.Type: ApplicationFiled: January 14, 2004Publication date: July 29, 2004Inventors: Dean Joseph Ippolito, Geoffrey Michael Gelman
-
Publication number: 20030119189Abstract: Disclosed are &bgr;-peptides and &bgr;-peptide conjugates that are capable of diffusing or otherwise being transported across the cell membranes of living cells. The &bgr;-peptides contain at least six &bgr;-amino acid residues, at leastsix of which are preferably &bgr;3-homoarginine residues. It has been found that when pharmacologically-active agents are conjugated to these types of &bgr;-peptides, the resulting conjugates (also disclosed herein) are also capable of diffusing or otherwise being transported across the cell membranes of living cells, including mammalian cells.Type: ApplicationFiled: September 18, 2002Publication date: June 26, 2003Inventors: Samuel H. Gellman, Naoki Umezawa, Michael A. Gelman, Ronald T. Raines, Terra Potocky